Abstract: An adapter configured for use in combination with a cap on a fuel cell having a closure formation, the cap having at least one leg portion and a corresponding foot extending from the leg, including a ring portion configured for engagement upon the closure formation of the fuel cell and including a top edge, a bottom edge, and a sidewall therebetween having an inner sidewall and an outer sidewall, a grooved portion defined by the inner sidewall, a convex gripping formation on the outer sidewall complementary to the closure formation, and at least one recessed formation adjacent the grooved portion for receiving the foot.

Abstract: The present invention provides a low cost, less toxic, anti-cancer immunotherapy which enhances the host's immune system ability to destroy or contain cancers, and also provides a diagnostic test for cancer. Specifically, the present invention provides monoclonal antibodies specific for, that is, specifically bind, oncofetal protein (OFP), a cancer cell product. Tumors treated with a single dose of the monoclonal antibodies against OFP are markedly reduced in size, and leukemic populations of cells treated with a single does of monoclonal antibodies against OFP are significantly decreased in number. Since the monoclonal antibodies of the present invention do not bind to tumor cells, the monoclonal antibody treatment overcomes the disadvantages associated with tumor cell targeting. Monoclonal antibodies to OFP offer a simple and inexpensive agent for use as a primary or adjuvant therapy against a wide variety of cancers and tumors in humans and other animals.

Abstract: The present invention provides a low cost, less toxic, anti-cancer immunotherapy which enhances the host's immune system ability to destroy or contain cancers, and also provides a diagnostic test for cancer. Specifically, the present invention provides monoclonal antibodies specific for, that is, specifically bind, oncofetal protein (OFP), a cancer cell product. Tumors treated with a single dose of the monoclonal antibodies against OFP are markedly reduced in size, and leukemic populations of cells treated with a single does of monoclonal antibodies against OFP are significantly decreased in number. Since the monoclonal antibodies of the present invention do not bind to tumor cells, the monoclonal antibody treatment overcomes the disadvantages associated with tumor cell targeting. Monoclonal antibodies to OFP offer a simple and inexpensive agent for use as a primary or adjuvant therapy against a wide variety of cancers and tumors in humans and other animals.

Abstract: The present invention provides a low cost, less toxic, anti-cancer immunotherapy which enhances the host's immune system ability to destroy or contain cancers, and also provides a diagnostic test for cancer. Specifically, the present invention provides monoclonal antibodies specific for, that is, specifically bind, oncofetal protein (OFP), a cancer cell product. Tumors treated with a single dose of the monoclonal antibodies against OFP are markedly reduced in size, and leukemic populations of cells treated with a single does of monoclonal antibodies against OFP are significantly decreased in number. Since the monoclonal antibodies of the present invention do not bind to tumor cells, the monoclonal antibody treatment overcomes the disadvantages associated with tumor cell targeting. Monoclonal antibodies to OFP offer a simple and inexpensive agent for use as a primary or adjuvant therapy against a wide variety of cancers and tumors in humans and other animals.

Abstract: The present invention provides a low cost, less toxic, anti-cancer immunotherapy which enhances the host's immune system ability to destroy or contain cancers, and also provides a diagnostic test for cancer. Specifically, the present invention provides monoclonal antibodies specific for, that is, specifically bind, oncofetal protein (OFP), a cancer cell product. Tumors treated with a single dose of the monoclonal antibodies against OFP are markedly reduced in size, and leukemic populations of cells treated with a single does of monoclonal antibodies against OFP are significantly decreased in number. Since the monoclonal antibodies of the present invention do not bind to tumor cells, the monoclonal antibody treatment overcomes the disadvantages associated with tumor cell targeting. Monoclonal antibodies to OFP offer a simple and inexpensive agent for use as a primary or adjuvant therapy against a wide variety of cancers and tumors in humans and other animals.

Abstract: The present invention describes a protocol for achieving a very high degree of anticarcinogenic (or chemopreventive or cancer preventative) activity through the combination of a low suboptimal dose of a D-glucarolactone-based dietary anticarcinogen (i.e., calcium glucarate or CGT) with a low suboptimal dose of retinoid-based anticarcinogen (4-hydroxyphenyl retinamide or HPR). Since synergism is obtained by this combination, these two anticarcinogens can be employed at dosages far below toxic levels and at dosages that are practical as a food supplement.

Abstract: The present invention describes a dietary supplement for achieving a very high degree of chemotherapeutic activity through the synergistic combination of a low suboptimal dose of a D-glucarolactone-based dietary anticarcinogen (calcium glucarate) with a low suboptimal dose of retinoid-based anticarcinogen (4-hydroxyphenyl retinamide).

Abstract: The present invention describes a protocol for achieving a very high degree of anticarcinogenic (chemopreventive and chemotherapeutic) activity through the combination of low suboptimal doses of a D-glucarolactone-based dietary anticarcinogen with low suboptimal doses of a retinoid-based anticarcinogen. Synergism is obtained by this combination and these two anticarcinogens can be employed at dosages far below toxic levels and at dosages that are practical as a food supplement.

Abstract: A method and kit are described for detecting the presence of cancers and pre-neoplastic cells that produce an oncofetal phosphoprotein having a molecular weight of approximately 60,000 and having the capacity to increase the release of ribonucleic acid from cell nuclei. The method involves detecting the presence of auto-antibodies to this oncofetal phosphoprotein in a subject suspected of suffering from a cancer or pre-neoplastic cells which produce this cancer marker protein. The kit includes purified oncofetal phosphoprotein.

Abstract: Materials can be screened for carcinogenic properties by administering them to test animals and assaying biological tissue, preferably plasma, for the presence of a 60K cancer-associated phosphoprotein. The test is applicable to a wide range of chemically-diverse carcinogens and is not restricted to carcinogens having one particular mode of action.

Abstract: A method for the reduction in vivo of the inappropriate levels of endogenous and environmental-derived compounds by inhibiting the activity of .beta.-glucuronidase in a mammal which comprises the administration to the mammal of an effective amount of a water insoluble, or sparingly soluble, sustained release precursor of glucarolactone or its analog is disclosed. The sustained release precursor of glucarolactone compound is selected from the group consisting of D-glucaric acid, D-galactaric acid, and L-idaric acid or derivatives or analogs. An orally administrable preparation of the sustained release precursor of glucarolactone compound is provided in the form of a capsule tablet, such that the glucarolactone or its analog is slowly released in the stomach of the treated animal or human.

Abstract: It has previously been shown that the serum from patients suffering from a wide range of cancers contains a cancer marker protein having the ability to release RNA from cell nuclei. This cancer marker protein is purified by taking the protein fraction precipitating between 30% and 50% saturated aqueous ammonium sulfate solution, dialyzing a solution of the protein fraction against TMK buffer, chromatographing the dialyzed protein on a molecular sieve and isolating the fraction having a molecular weight of about 60,000; and removing albumin. Injection of the purified protein into rabbits, preparation of serum from blood of the rabbits and absorption of the sera with normal plasma fraction produces at antibody specific to the cancer marker protein and therefore useful in a radioimmunoassay or ELISA test for a wide variety of cancers.

Abstract: Described is Al-Mg Sheet, in annealed condition, which has good formability and is further characterized structurally by its ability to be formed in the manufacture of sheet-metal products without being marked by Type A Luder lines. Also described are method aspects of producing such sheet, including the steps of selectively annealing and quenching followed by stretching.